Rita Jermyn, MD
Advanced Heart Failure and Transplant Cardiology · Roslyn, NYNPI 1811140627
Payments from drug & device makers
Across 641 payments — averaging $1548.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$317K
- Abbott$248K
- Edwards Lifesciences$133K
- Medtronic$75K
- Cvrx, Inc.$62K
- Bayer$56K
- plus $103K from 27 others
What the payments were for
- Consulting fees$29,39034%
- Speaking & faculty fees$39,86346%
- Grants$1,2221%
- Travel & lodging$5,7937%
- Food & beverage$10,48412%
- Education$2060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 80 | $316,702 |
| Abbott | 206 | $247,766 |
| Edwards Lifesciences | 19 | $132,612 |
| Medtronic | 24 | $74,591 |
| Cvrx, Inc. | 12 | $61,922 |
| Bayer | 35 | $55,692 |
| Novo Nordisk AS | 138 | $42,669 |
| Boehringer Ingelheim | 6 | $37,677 |
| Kestra Medical Technology Services, Inc. | 8 | $9,007 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $5,409 |
| Amgen | 1 | $3,000 |
| Boston Scientific | 1 | $1,222 |
| Alnylam Pharmaceuticals Inc. | 35 | $867 |
| Akcea Therapeutics, Inc. | 12 | $690 |
| Vifor Pharma, Inc. | 12 | $393 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $338 |
| BD | 1 | $275 |
| Covidien LP | 1 | $266 |
| Johnson & Johnson | 2 | $250 |
| E.r. Squibb & Sons, L.L.C. | 4 | $205 |
| Sobi, Inc | 1 | $150 |
| Scpharmaceuticals Inc. | 5 | $131 |
| United Therapeutics Corporation | 2 | $128 |
| Amarin Pharma, Inc. | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 2 | $123 |
| Arbor Pharmaceuticals, Inc. | 5 | $81 |
| AstraZeneca | 4 | $72 |
| Merck | 3 | $56 |
| Abiomed | 2 | $49 |
| Impulse Dynamics (USA) Inc. | 2 | $46 |
| Bridgebio Pharma, Inc. | 2 | $36 |
| Sensible Medical Innovations Inc | 1 | $21 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$44,596
- CardioMEMS HF System$12,675
- Assure WCD$8,750
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,966
- CARDIOMEMS$1,930
- GENERAL TACHY$1,222
- HeartMate 3 Left Ventricular Assist Device$750
- TEGSEDI$696
- Adempas$600
- AMVUTTRA$272
- JARDIANCE$250
- XARELTO$250
- VERQUVO$207
- Veltassa$200
- Optis Coronary Imaging System$170
- HeartMate$165
- Vascepa$125
- CAMZYOS$123
- Quadra Assura CRT Defibrillator$120
- Mitra Clip system$103
How this compares
$992,586 in reported general payments places this provider in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 66 | $886,599 |
| EntrestoSacubitril/Valsartan | 169 | $278,030 |
| JardianceEmpagliflozin | 64 | $102,083 |
| FarxigaDapagliflozin Propanediol | 61 | $72,759 |
| EliquisApixaban | 54 | $68,341 |
| XareltoRivaroxaban | 17 | $19,862 |
| Bosentan | 14 | $16,284 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $12,539 |
| Bumetanide | 74 | $3,509 |
| Metoprolol Succinate | 173 | $3,108 |
| Torsemide | 94 | $2,029 |
| Amiodarone Hcl | 11 | $1,200 |
| Eplerenone | 14 | $1,142 |
| Spironolactone | 155 | $1,078 |
| Ezetimibe | 46 | $1,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan | $123 | $902,88380 claims |
| NovartisEntresto | $316,702 | $278,030169 claims |
| Boehringer IngelheimJardiance | $37,677 | $102,08364 claims |
| AstraZenecaFarxiga | $72 | $72,75961 claims |
| PfizerEliquis | $18 | $68,34154 claims |
| Johnson & JohnsonXarelto | $250 | $19,86217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Roslyn
- Mathew MaurerNew York$5M
- Evelyn HornNew York$2.9M
- Johanna ContrerasNew York$1.4M
- Parag GoyalNew York$1.1M
- James LyonsPoughkeepsie$954K
- Nir UrielNew York$884K
- Tajinderpal SaraonNew York$618K
- Kelly AxsomNew York$502K
- Scott FeitellRochester$484K
- Sean PinneyNew York$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.